Triptolide (TP), a main bioactive component of Tripterygium wilfordii Hook F., is a promising agent for treatment of
autoimmune diseases. However, a high incidence of dose-limiting hepatotoxicity was observed in the clinic. Sandwich-cultured rat hepatocyte model was used in this study to identify the involvement of
P-glycoprotein (
P-gp) in TP disposition and to evaluate TP-induced hepatotoxicity after modulation of
P-gp by the known inhibitors,
ritonavir and
tariquidar, and known inducers,
phenobarbital,
quercetin, and H(2)O(2). Our data showed that biliary clearance of TP reduced 73.7% and 84.2% upon treatment of
ritonavir (25 µM) and
tariquidar (5 µM), respectively. In contrast, increases of 346%, 280%, and 273% in biliary clearance of TP were observed with treatment of
phenobarbital (1.0 mM),
quercetin (20 µM), and H(2)O(2) (0.5 mM), respectively. The TP-induced hepatotoxicity increased by twofold when CYP activity was blocked by
1-aminobenzotriazole, suggesting that CYP and
P-gp may both contribute to the detoxification of TP in the SCRH model. In addition, hepatotoxicity and the expression of apoptosis
proteins Bax and Bcl-2 were correlated qualitatively with the TP exposure duration and its intracellular concentration, which, in turn, can be modulated by
P-gp inhibitors or inducers. Our results for the first time demonstrated that in addition to CYP-mediated metabolism,
P-gp also plays an important role in the disposition of TP and TP-induced hepatotoxicity. Thus, the modulation of canalicular
P-gp has a potential to cause drug-drug interaction between TP and the coadministered
P-gp inhibitors or inducers in the clinic.